Novo Nordisk (NVO.N) rose 5.5% in premarket trading after the U.S. Food and Drug Administration (FDA) said the shortage of semaglutide injection Ozempic has been resolved.

2025-02-21 22:20:18

Novo Nordisk

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Intel's US stock rose more than 10% in the night trading
                            2025-03-12

                                    360 launches DS large model security solution to protect the development of DeepSeek
                            2025-03-12

                                    JD.com's revenue in Q4 2024 is expected to be 347 billion yuan
                            2025-03-06

                                    Daiwa Securities raised Alibaba Group's target price from HK$165 to HK$175
                            2025-03-07

                                    Ouye Semiconductor completed B2 round of financing of hundreds of millions of yuan to promote large-scale application of products
                            2025-03-13